ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2294

Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production

Lieke E.J.M. Scheepers1,2, A. Boonen1,2, P.C. Dagnelie2,3,4, M.T. Schram3,5, C.J.H, van der Kallen3,5, R.M.A. Henry3,5, A.A. Kroon3,5, C.D.A. Stehouwer3,6 and I.C.W. Arts3,4,7, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, 2CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 3CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 4Department of Epidemiology, Maastricht University, Maastricht, The Netherlands, Maastricht, Netherlands, 5Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, 6Internal Medicine, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Netherlands, 7MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: hypertension, hyperuricemia and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Blood pressure and hypertension are associated with uric acid, the end product of purine catabolism, but the underlying mechanism remainds unclear. During the final stage of purine metabolism, xanthine oxidase (XO) breaks down hypoxanthine to xanthine, and xanthine to uric acid, while reactive oxygen species (ROS) are formed. Accumulation of ROS by increased uric acid production has been suggested as a possible underlying mechanism for the association between uric acid and high blood pressure. We therefore investigated whether (i) serum uric acid concentration and/or (ii) 24h urinary uric acid excretion, as proxy for uric acid production, are associated with ambulatory blood pressure and hypertension.

Methods:  Cross-sectional analyses were conducted among 2660 individuals (52% men, mean age 60.0±8.2 years; 26.7% type 2 diabetes [by design]) from The Maastricht Study. Multivariable linear and logistic regression analyses were performed to investigate the association of serum uric acid concentration and 24h urinary uric acid excretion with 24h pulse pressure (PP), 24h mean arterial pressure (MAP) and hypertension. Hypertension was defined as mean 24h systolic BP of ≥ 135 mmHg, 24h DBP ≥ 85 mmHg, and/or the use of anti-hypertensive medication. Analyses were adjusted for sex, age, glucose metabolism status, and further for treatment of diabetes and hypertension, body mass index, smoking behavior, alcohol consumption, education, and eGFR (in the logistic analyses, no adjustment for anti-hypertensive medication). Analyses exploring the role of serum uric acid were additionally adjusted for 24h urine uric acid excretion, whereas analyses exploring the role of 24h urine uric acid excretion were additionally adjusted for serum uric acid concentration and fractional excretion of uric acid (FEUA).

Results:  In fully adjusted analyses, serum uric acid concentration (per standard deviation [SD] of 330 µmol/L) was associated with higher MAP (β 0.50 mmHg (95% confidence [CI], 0.14 to 0.88; P­=0.01) and positively associated with hypertension (odds ratio 1.29; CI, 1.14 to 1.46; P­-value <0.001). Twenty-four-hour urinary uric acid excretion (per SD 141 mg/day/1.73m2) was associated with higher MAP (β 0.85 mmHg; CI, 0.30 to 1.40; P­-value <0.001). There was no significant association between serum and 24h urinary uric acid excretion with PP. There was no interaction for the aforementioned associations with sex or age.

Conclusion:  We found evidence of associations between serum uric acid concentration with MAP and hypertension. Additionally, 24h uric acid excretion was associated with MAP. This indicates that both serum uric acid concentration and uric acid production are, independent of each other, associated with blood pressure.


Disclosure: L. E. J. M. Scheepers, None; A. Boonen, None; P. C. Dagnelie, None; M. T. Schram, None; C. J. H. van der Kallen, None; R. M. A. Henry, None; A. A. Kroon, None; C. D. A. Stehouwer, None; I. C. W. Arts, None.

To cite this abstract in AMA style:

Scheepers LEJM, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, Kroon AA, Stehouwer CDA, Arts ICW. Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/uric-acid-production-and-blood-pressure-the-role-of-uric-acid-concentration-as-well-as-uric-acid-production/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uric-acid-production-and-blood-pressure-the-role-of-uric-acid-concentration-as-well-as-uric-acid-production/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology